Tokyo Tape
Sign in
← Sakai Chemical Industry

Half-year report · Q2

4078.TEDINET S100UO2I
Period2024-04-01 → 2024-09-30
Filed2024-11-08
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed

Amended by S100V7D8 (2025-02-07).

Key figures · 45
MetricValuePeriodScopeSource row
Revenue¥41.9bn2024-04-01 → 2024-09-30Cons.Net sales
Revenue¥82.1bn2023-04-01 → 2024-03-31Cons.Net sales (5-year summary)
Revenue¥40.5bn2023-04-01 → 2023-09-30Cons.Net sales
Operating income¥2.6bn2024-04-01 → 2024-09-30Cons.Operating income
Operating income¥917m2023-04-01 → 2023-09-30Cons.Operating income
Ordinary income¥2.6bn2024-04-01 → 2024-09-30Cons.Ordinary income
Ordinary income¥3.1bn2023-04-01 → 2024-03-31Cons.Ordinary income loss (5-year summary)
Ordinary income¥885m2023-04-01 → 2023-09-30Cons.Ordinary income
Profit before tax¥2.4bn2024-04-01 → 2024-09-30Cons.Income before income taxes
Profit before tax¥773m2023-04-01 → 2023-09-30Cons.Income before income taxes
Net income (owners)¥1.7bn2024-04-01 → 2024-09-30Cons.Profit loss attributable to owners of parent
Net income (owners)−¥7.1bn2023-04-01 → 2024-03-31Cons.Profit loss attributable to owners of parent (5-year summary)
Net income (owners)−¥2.0bn2023-04-01 → 2023-09-30Cons.Profit loss attributable to owners of parent
Net income¥1.8bn2024-04-01 → 2024-09-30Cons.Profit loss
Net income−¥1.8bn2023-04-01 → 2023-09-30Cons.Profit loss
Total assets¥121.2bnat 2024-09-30Cons.Assets
Total assets¥125.4bnat 2024-03-31Cons.Assets
Total assets¥131.6bnat 2023-09-30Cons.Total assets (5-year summary)
Total liabilities¥44.1bnat 2024-09-30Cons.Liabilities
Total liabilities¥50.0bnat 2024-03-31Cons.Liabilities
Net assets / equity¥77.1bnat 2024-09-30Cons.Net assets
Net assets / equity¥75.5bnat 2024-03-31Cons.Net assets
Net assets / equity¥80.7bnat 2023-09-30Cons.Net assets (5-year summary)
Cash and deposits¥14.8bnat 2024-09-30Cons.Cash and deposits
Cash and deposits¥16.6bnat 2024-03-31Cons.Cash and deposits
Cash & equivalents¥14.6bnat 2024-09-30Cons.Cash and cash equivalents
Cash & equivalents¥16.5bnat 2024-03-31Cons.Cash and cash equivalents
Cash & equivalents¥15.5bnat 2023-09-30Cons.Cash and cash equivalents
Cash & equivalents¥12.2bnat 2023-03-31dCons.Cash and cash equivalents
Operating cash flow¥7.4bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in operating activities
Operating cash flow¥6.9bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in operating activities (5-year summary)
Operating cash flow¥3.2bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in operating activities
Investing cash flow−¥3.0bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in investment activities
Investing cash flow−¥4.0bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in investing activities (5-year summary)
Investing cash flow−¥1.6bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in investment activities
Financing cash flow−¥6.6bn2024-04-01 → 2024-09-30Cons.Net cash provided by used in financing activities
Financing cash flow¥1.3bn2023-04-01 → 2024-03-31Cons.Net cash provided by used in financing activities (5-year summary)
Financing cash flow¥1.6bn2023-04-01 → 2023-09-30Cons.Net cash provided by used in financing activities
EPS (basic)¥107.712024-04-01 → 2024-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-437.652023-04-01 → 2024-03-31Cons.Basic earnings loss per share (5-year summary)
EPS (basic)¥-125.532023-04-01 → 2023-09-30Cons.Basic earnings loss per share (5-year summary)
EPS (diluted)¥97.232024-04-01 → 2024-09-30Cons.Diluted earnings per share (5-year summary)
Equity ratio62.7%at 2024-09-30Cons.Equity to asset ratio (5-year summary)
Equity ratio59.3%at 2024-03-31Cons.Equity to asset ratio (5-year summary)
Equity ratio60.5%at 2023-09-30Cons.Equity to asset ratio (5-year summary)

Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.

Segments · 30
SegmentItemPeriodValue
Reconciling Itemsreconcilingrevenue2024-04-01 → 2024-09-30−¥910m
Reconciling Itemsreconcilingrevenue intersegment2024-04-01 → 2024-09-30−¥910m
Reconciling Itemsreconcilingsegment profit2024-04-01 → 2024-09-30−¥1.2bn
jpcrp040300-q2r_E00780-000Chemicalreportable segmentrevenue2024-04-01 → 2024-09-30¥38.4bn
jpcrp040300-q2r_E00780-000Chemicalreportable segmentrevenue external2024-04-01 → 2024-09-30¥37.6bn
jpcrp040300-q2r_E00780-000Chemicalreportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥798m
jpcrp040300-q2r_E00780-000Chemicalreportable segmentsegment profit2024-04-01 → 2024-09-30¥3.8bn
jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segmentrevenue2024-04-01 → 2024-09-30¥4.4bn
jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segmentrevenue external2024-04-01 → 2024-09-30¥4.3bn
jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segmentrevenue intersegment2024-04-01 → 2024-09-30¥111m
jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segmentsegment profit2024-04-01 → 2024-09-30¥65m
—segment totalrevenue2024-04-01 → 2024-09-30¥42.8bn
—segment totalrevenue external2024-04-01 → 2024-09-30¥41.9bn
—segment totalrevenue intersegment2024-04-01 → 2024-09-30¥910m
—segment totalsegment profit2024-04-01 → 2024-09-30¥3.8bn
Reconciling Itemsreconcilingrevenue2023-04-01 → 2023-09-30−¥635m
Reconciling Itemsreconcilingrevenue intersegment2023-04-01 → 2023-09-30−¥635m
Reconciling Itemsreconcilingsegment profit2023-04-01 → 2023-09-30−¥1.1bn
jpcrp040300-q2r_E00780-000Chemicalreportable segmentrevenue2023-04-01 → 2023-09-30¥36.8bn
jpcrp040300-q2r_E00780-000Chemicalreportable segmentrevenue external2023-04-01 → 2023-09-30¥36.3bn
jpcrp040300-q2r_E00780-000Chemicalreportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥498m
jpcrp040300-q2r_E00780-000Chemicalreportable segmentsegment profit2023-04-01 → 2023-09-30¥1.9bn
jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segmentrevenue2023-04-01 → 2023-09-30¥4.3bn
jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segmentrevenue external2023-04-01 → 2023-09-30¥4.2bn
jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segmentrevenue intersegment2023-04-01 → 2023-09-30¥136m
jpcrp040300-q2r_E00780-000Medicine And Health Carereportable segmentsegment profit2023-04-01 → 2023-09-30¥144m
—segment totalrevenue2023-04-01 → 2023-09-30¥41.1bn
—segment totalrevenue external2023-04-01 → 2023-09-30¥40.5bn
—segment totalrevenue intersegment2023-04-01 → 2023-09-30¥635m
—segment totalsegment profit2023-04-01 → 2023-09-30¥2.0bn

Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.

All source rows · 516
ItemContextValueUnit
Current liabilitiesPrior1YearInstant31757000000JPY
Current liabilitiesCurrentQuarterInstant25755000000JPY
Convertible bond type bonds with subscription rights to sharesPrior1YearInstant3000000000JPY
Convertible bond type bonds with subscription rights to sharesCurrentQuarterInstant3000000000JPY
Long term loans payablePrior1YearInstant8930000000JPY
Long term loans payableCurrentQuarterInstant9213000000JPY
Provision for environmental measures nclPrior1YearInstant141000000JPY
Provision for environmental measures nclCurrentQuarterInstant160000000JPY
Net defined benefit liabilityPrior1YearInstant4750000000JPY
Net defined benefit liabilityCurrentQuarterInstant4617000000JPY
Deferred tax liabilitiesPrior1YearInstant1136000000JPY
Deferred tax liabilitiesCurrentQuarterInstant1051000000JPY
Other nclPrior1YearInstant261000000JPY
Other nclCurrentQuarterInstant306000000JPY
Noncurrent liabilitiesPrior1YearInstant18220000000JPY
Noncurrent liabilitiesCurrentQuarterInstant18350000000JPY
LiabilitiesPrior1YearInstant49978000000JPY
LiabilitiesCurrentQuarterInstant44106000000JPY
Capital stockPrior1YearInstant21838000000JPY
Capital stockCurrentQuarterInstant21838000000JPY
Capital surplusPrior1YearInstant16727000000JPY
Capital surplusCurrentQuarterInstant16773000000JPY
Retained earningsPrior1YearInstant34334000000JPY
Retained earningsCurrentQuarterInstant35513000000JPY
Treasury stockPrior1YearInstant-1716000000JPY
Treasury stockCurrentQuarterInstant-1700000000JPY
Shareholders equityPrior1YearInstant71183000000JPY
Shareholders equityCurrentQuarterInstant72424000000JPY
Valuation difference on available for sale securitiesPrior1YearInstant2340000000JPY
Valuation difference on available for sale securitiesCurrentQuarterInstant2359000000JPY
Deferred gains or losses on hedgesPrior1YearInstant10000000JPY
Deferred gains or losses on hedgesCurrentQuarterInstant-24000000JPY
Foreign currency translation adjustmentPrior1YearInstant572000000JPY
Foreign currency translation adjustmentCurrentQuarterInstant1087000000JPY
Remeasurements of defined benefit plansPrior1YearInstant250000000JPY
Remeasurements of defined benefit plansCurrentQuarterInstant221000000JPY
Valuation and translation adjustmentsPrior1YearInstant3173000000JPY
Valuation and translation adjustmentsCurrentQuarterInstant3642000000JPY
Subscription rights to sharesPrior1YearInstant35000000JPY
Subscription rights to sharesCurrentQuarterInstant35000000JPY
Non controlling interestsPrior1YearInstant1074000000JPY
Non controlling interestsCurrentQuarterInstant1038000000JPY
Net assetsPrior1YearInstant75466000000JPY
Net assetsCurrentQuarterInstant77140000000JPY
Liabilities and net assetsPrior1YearInstant125445000000JPY
Liabilities and net assetsCurrentQuarterInstant121246000000JPY
Net salesPrior1YTDDuration40471000000JPY
Net salesCurrentYTDDuration41874000000JPY
Cost of salesPrior1YTDDuration32596000000JPY
Cost of salesCurrentYTDDuration32241000000JPY

Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.

Data checks · 14 of 14 passed
balance sheet identityconsolidated 2024-03-31pass rounding
balance sheet identityconsolidated 2024-09-30pass
dei present pass
period resolution pass
statement vs summary · net assetsconsolidated 2024-03-31pass
statement vs summary · net assetsconsolidated 2024-09-30pass
statement vs summary · net income attributable to parentconsolidated 2023-04-01/2023-09-30pass
statement vs summary · net income attributable to parentconsolidated 2024-04-01/2024-09-30pass
statement vs summary · operating cash flowconsolidated 2023-04-01/2023-09-30pass
statement vs summary · operating cash flowconsolidated 2024-04-01/2024-09-30pass
statement vs summary · revenueconsolidated 2023-04-01/2023-09-30pass
statement vs summary · revenueconsolidated 2024-04-01/2024-09-30pass
statement vs summary · total assetsconsolidated 2024-03-31pass
statement vs summary · total assetsconsolidated 2024-09-30pass